Repeat-cycle study of high-dose intravenous (iv) 4162W94 anti-CD4 monoclonal antibody (mAb) in rheumatoid arthritis (RA).

被引:0
|
作者
Panavi, GS
Choy, EHS
Emery, P
Madden, S
Breedveld, FC
Kraan, MC
Kalden, JR
Rascu, A
Brown, JCC
Johnston, JM
机构
[1] Guys & Kings Coll Hosp, London, England
[2] Univ Leeds, Leeds, W Yorkshire, England
[3] Leiden Univ Hosp, Leiden, Netherlands
[4] Univ Erlangen Nurnberg, D-8520 Erlangen, Germany
[5] Glaxo Wellcome, Res Triangle Pk, NC USA
来源
ARTHRITIS AND RHEUMATISM | 1998年 / 41卷 / 09期
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
139
引用
收藏
页码:S56 / S56
页数:1
相关论文
共 27 条
  • [11] T cell hypothesis in rheumatoid arthritis (RA) tested by humanized non-depleting anti-CD4 monoclonal antibody (mAb) treatment .3. Immunological effects.
    Connolly, DJA
    Choy, EHS
    Rapson, N
    Regan, T
    Kingsley, GH
    Johnston, JM
    Panayi, GS
    ARTHRITIS AND RHEUMATISM, 1996, 39 (09): : 1302 - 1302
  • [12] Immunological markers of response in a multi-dose protocol 7002 using an immunomodulating, nondepleting Primatized(TM) anti-CD4 monoclonal antibody in rheumatoid arthritis (RA).
    Solinger, A
    Paxton, H
    Wev, K
    Yocum, D
    FASEB JOURNAL, 1996, 10 (06): : 1813 - 1813
  • [13] Clinical Pharmacology of an Anti-CD4 Monoclonal Antibody with Enhanced FcRn Binding Affinity in a Phase I Study for Rheumatoid Arthritis
    Scheerens, Heleen
    Zheng, Yanan
    Davis, John
    Su, Zheng
    Deng, Rong
    Fischer, Sally
    Woods, Cynthia
    Fielder, Paul
    Stefanich, Eric
    CLINICAL IMMUNOLOGY, 2010, 135 : S85 - S85
  • [14] T cell hypothesis in rheumatoid arthritis (RA) tested by humanised non-depleting anti-CD4 monoclonal antibody (mAb) treatment .2. Clinical activity is related to pharmacodynamic effects
    Choy, EHS
    Connolly, DJA
    Regan, T
    Manna, VK
    Rapson, N
    Kingsley, GH
    Panayi, GS
    Johnston, JM
    IMMUNOLOGY, 1996, 89 : OG378 - OG378
  • [15] Cell hypothesis in rheumatoid arthritis (RA) tested by humanized non-depleting anti-CD4 monoclonal antibody (mAb) treatment .1. Suppression of disease activity and acute phase response
    Panayi, GS
    Choy, EHS
    Connolly, DJA
    Regan, T
    Manna, VK
    Rapson, N
    Kingsley, GH
    Johnston, JM
    ARTHRITIS AND RHEUMATISM, 1996, 39 (09): : 1300 - 1300
  • [16] Cell hypothesis in rheumatoid arthritis (RA) tested by humanized non-depleting anti-CD4 monoclonal antibody (mAb) treatment .2. Clinical activity is related to pharmacodynamic effects.
    Choy, EHS
    Connolly, DJA
    Regan, T
    Manna, VK
    Rapson, N
    Kingsley, GH
    Panayi, GS
    Johnston, JM
    ARTHRITIS AND RHEUMATISM, 1996, 39 (09): : 1301 - 1301
  • [17] Clinical and immunologic effects of a PRIMATIZED® anti-CD4 monoclonal antibody in active rheumatoid arthritis:: Results of a phase I, single dose, dose escalating trial
    Yocum, DE
    Solinger, AM
    Tesser, J
    Gluck, O
    Cornett, M
    O'Sullivan, F
    Nordensson, K
    Dallaire, B
    Shen, CD
    Lipani, J
    JOURNAL OF RHEUMATOLOGY, 1998, 25 (07) : 1257 - 1262
  • [18] Immunological markers of response in a multi-dose protocol 7002 using an immunomodulating, non-depleting primatized(TM) anti-CD4 monoclonal antibody in rheumatoid arthritis (RA)
    Solinger, A
    Paxton, H
    Wey, K
    Yocum, D
    FASEB JOURNAL, 1996, 10 (03): : 2552 - 2552
  • [19] T cell hypothesis in rheumatoid arthritis (RA) tested by humanised non-depleting anti-CD4 monoclonal antibody (mAb) treatment .1. Suppression of disease activity and acute phase response.
    Panayi, GS
    Choy, EHS
    Connolly, DJA
    Manna, VK
    Regan, T
    Rapson, N
    Kingsley, GH
    Johnston, JM
    IMMUNOLOGY, 1996, 89 : OG379 - OG379
  • [20] RESULTS OF A MULTIDOSE PROTOCOL-7002 USING AN IMMUNOMODULATING, NON-DEPLETING PRIMATIZED(TM) ANTI-CD4 MONOCLONAL-ANTIBODY IN RHEUMATOID-ARTHRITIS (RA)
    KAINE, J
    SOLLINGER, A
    YOCUM, D
    LIPANI, J
    KLAS, P
    TESSER, J
    WIESENHUTTER, C
    OSULLIVAN, F
    SHUMAN, S
    RIGBY, W
    ARTHRITIS AND RHEUMATISM, 1995, 38 (09): : 195 - 195